Completed PHASE2 INTERVENTIONAL 2-arm NCT02341378

Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis

A Multicenter, Single-blind, Phase 2A Clinical Trial to Evaluate the Efficacy and Safety of TissueGene-C, a Cell-mediated Gene Therapy, in Degenerative Arthritis Patients

Sponsor: Kolon Life Science

Conditions Degenerative Arthritis

Interventions TissueGene-C(High dose) TissueGene-C(Low dose)

Updated 6 times since 2017 Last updated: Jan 21, 2015 Started: Aug 31, 2009 Primary completion: Jun 30, 2010 Completion: Oct 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Degenerative Arthritis, this trial is completed. The trial is conducted by Kolon Life Science and has accumulated 6 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kolon Life Science

Data source: Kolon Life Science

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gangnam-gu, South Korea
• Seoul, South Korea